List of nationally authorised medicinal products

Size: px
Start display at page:

Download "List of nationally authorised medicinal products"

Transcription

1 20 July 2016 EMA/270645/2015 Procedure Management and Committees Support Active substance: apomorphine Procedure no.: PSUSA/ / Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0) Facsimile +44 (0) Send a question via our website An agency of the European Union European Medicines Agency, Reproduction is authorised provided the source is acknowledged.

2 Infusionslösung National Number AT/H/0364/ EVER NEU PHARMA GMBH AT Dacepton 5 mg /ml oplossing voor infusie AT/H/0364/002 BE EVER NEU PHARMA GMBH BE Dacepton 5 mg/ml infusionsvæske, opløsning infusioonilahus AT/H/0364/002/DC EVER NEU PHARMA GMBH DK AT/H/0364/ EVER NEU PHARMA GMBH EE Dopaceptin 5 mg/ml Solution pour perfusion AT/H/0364/ EVER NEU PHARMA GMBH FR Dopaceptin 5 mg/ml Solution pour perfusion AT/H/0364/ EVER NEU PHARMA GMBH FR AT/H/0364/002 OGYI-T-22316/ EVER NEU PHARMA GMBH HU oldatos infúzió 10 Infusionslösung AT/H/0364/ EVER NEU PHARMA GMBH DE infúzny roztok AT/H/0364/002 27/0099/14-S EVER NEU PHARMA GMBH SK infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/008 EVER NEU PHARMA GMBH LT EMA/578674/2016 Page 2/21

3 infuzinis tirpalas National Number AT/H/0364/002 LT/1/11/2759/009 EVER NEU PHARMA GMBH LT infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/010 EVER NEU PHARMA GMBH LT infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/011 EVER NEU PHARMA GMBH LT infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/012 EVER NEU PHARMA GMBH LT infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/013 EVER NEU PHARMA GMBH LT infuzinis tirpalas AT/H/0364/002 LT/1/11/2759/014 EVER NEU PHARMA GMBH LT solution for infusion AT/H/0364/002 PA1774/001/002 EVER NEU PHARMA GMBH IE šķīdums infūzijām AT/H/0364/ EVER NEU PHARMA GMBH LV oplossing voor infusie AT/H/0364/002 RVG EVER NEU PHARMA GMBH NL EMA/578674/2016 Page 3/21

4 infusjonsvæske, oppløsning soluţie perfuzabilă National Number AT/H/0364/002/DC EVER NEU PHARMA GMBH NO AT/H/0364/ /2014/01-05 EVER NEU PHARMA GMBH infusionsvätska, lösning AT/H/0364/ EVER NEU PHARMA GMBH SE raztopina za infundiranje AT/H/0364/ I-1007/14 EVER NEU PHARMA GMBH SI raztopina za infundiranje AT/H/0364/ I-1008/14 EVER NEU PHARMA GMBH SI raztopina za infundiranje AT/H/0364/ I-1009/14 EVER NEU PHARMA GMBH SI raztopina za infundiranje AT/H/0364/ I-1010/14 EVER NEU PHARMA GMBH SI raztopina za infundiranje AT/H/0364/ I-1011/14 EVER NEU PHARMA GMBH SI solution for infusion AT/H/0364/002 PL 40369/0003 EVER NEU PHARMA GMBH UK EMA/578674/2016 Page 4/21

5 Дацептон 5 mg/ml инфузионен разтвор National Number AT/H/0364/002/DC EVER NEU PHARMA GMBH BG AT/H/0364/001 PA1774/001/001 EVER NEU PHARMA GMBH IE AT/H/0364/001/DC EVER NEU PHARMA GMBH DE AT/H/0364/ EVER NEU PHARMA GMBH EE Solution for injection or infusion Injektions- /Infusionslösung, süste- või infusioonilahus solución inyectable y para perfusión EFG Dacepton 10 mg /ml oldatos injekció vagy infúzió Dacepton 10 mg /ml oplossing voor injectie of infusie injeksjons- /infusjonsvæske, oppløsning injektions- /infusionsvätska, lösning AT/H/0364/ EVER NEU PHARMA GMBH ES AT/H/0364/001 OGYI-T-22316/01-03 EVER NEU PHARMA GMBH HU AT/H/0364/001 RVG EVER NEU PHARMA GMBH NL AT/H/0364/001/DC EVER NEU PHARMA GMBH NO AT/H/0364/ EVER NEU PHARMA GMBH SE EMA/578674/2016 Page 5/21

6 National Number AT/H/0364/ I-1512/12 EVER NEU PHARMA GMBH SI AT/H/0364/001 PL 40369/0001 EVER NEU PHARMA GMBH UK AT/H/0364/001 BE EVER NEU PHARMA GMBH BE AT/H/0364/001/DC EVER NEU PHARMA GMBH FI AT/H/0364/ EVER NEU PHARMA GMBH ES AT/H/0364/ EVER NEU PHARMA GMBH FI raztopina za injiciranje/infundiranje Solution for injection or infusion solution injectable/pour perfusion injektions- /infusionsvätska, lösning solución para perfusión EFG Dacepton 5 mg /ml infuusioneste, liuos Injektions- /Infusionslösung, injekcní/infuzní roztok AT/H/0364/001/DC EVER NEU PHARMA GMBH AT AT/H/0364/001 27/353/11-C EVER NEU PHARMA GMBH CZ injekcinis / infuzinis tirpalas AT/H/0364/001 LT/1/11/2759/001 EVER NEU PHARMA GMBH LT EMA/578674/2016 Page 6/21

7 injekcinis / infuzinis tirpalas injekcinis / infuzinis tirpalas injekcinis / infuzinis tirpalas injekcinis / infuzinis tirpalas injekcinis / infuzinis tirpalas injekcinis / infuzinis tirpalas šķīdums injekcijām vai infūzijām DACEPTON, 10 mg/ml, roztwór do wstrzykiwań / do infuzji solutie injectabila/perfuzabila National Number AT/H/0364/001 LT/1/11/2759/002 EVER NEU PHARMA GMBH LT AT/H/0364/001 LT/1/11/2759/003 EVER NEU PHARMA GMBH LT AT/H/0364/001 LT/1/11/2759/004 EVER NEU PHARMA GMBH LT AT/H/0364/001 LT/1/11/2759/005 EVER NEU PHARMA GMBH LT AT/H/0364/001 LT/1/11/2759/006 EVER NEU PHARMA GMBH LT AT/H/0364/001 LT/1/11/2759/007 EVER NEU PHARMA GMBH LT AT/H/0364/ EVER NEU PHARMA GMBH LV AT/H/0364/ EVER NEU PHARMA GMBH PL AT/H/0364/ /2011/01 EVER NEU PHARMA GMBH EMA/578674/2016 Page 7/21

8 Injekčný a infúzny roztok National Number AT/H/0364/001 27/0360/11-S EVER NEU PHARMA GMBH SK solutie injectabila/perfuzabila solutie injectabila/perfuzabila solutie injectabila/perfuzabila solutie injectabila/perfuzabila solutie injectabila/perfuzabila solutie injectabila/perfuzabila Инжекционен/инфузион ен разтвор Dacepton, injektions- og infusionsvæske, opløsning AT/H/0364/ /2011/02 EVER NEU PHARMA GMBH AT/H/0364/ /2011/03 EVER NEU PHARMA GMBH AT/H/0364/ /2011/04 EVER NEU PHARMA GMBH AT/H/0364/ /2011/05 EVER NEU PHARMA GMBH AT/H/0364/ /2011/06 EVER NEU PHARMA GMBH AT/H/0364/ /2011/07 EVER NEU PHARMA GMBH AT/H/0364/ EVER NEU PHARMA GMBH BG AT/H/0364/ EVER NEU PHARMA GMBH DK EMA/578674/2016 Page 8/21

9 APO-go Ampullen 10 National Number UK/H/0342/ BRITANNIA mg/ml Injektions- /Infusionslösung APO-go 10 mg/ml UK/H/0342/ BRITANNIA injektions- /infusionsvätska, lösning APO-go Ampul UK/H/0342/ BRITANNIA AT SE DK APO-go Ampullen 10 mg/ml Injektions- /Infusionslösung APO-go 10 mg/ml injekčný alebo infúzny roztok APO-GO-AMP 10 mg/ml oplossing voor injectie of infusie UK/H/0342/ BRITANNIA UK/H/0342/002 27/0461/11-S BRITANNIA UK/H/0342/002 BE BRITANNIA UK/H/0342/ /2012/01 BRITANNIA DE SK BE Apo-go 10mg/ml Solução injetável ou para perfusão APO-go 10 mg/ml raztopina za injiciranje ali infundiranje v ampuli UK/H/0342/ BRITANNIA UK/H/0342/ I-673/12 BRITANNIA PT SI EMA/578674/2016 Page 9/21

10 APO-go AMPOULES 10 mg/ml Solution for Injection or Infusion APO-GO-AMP 10 mg/ml oplossing voor injectie of infusie Apo-go 10mg/ml Solução injetável ou para perfusão Apo-go 10mg/ml Solução injetável ou para perfusão Apo-go 10mg/ml Solução injetável ou para perfusão Apo-go 10mg/ml Solução injetável ou para perfusão Apo-go 10mg/ml Solução injetável ou para perfusão National Number UK/H/0342/002 PA0356/010/002 BRITANNIA UK/H/0342/002 BE BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ /2012/03 BRITANNIA IE BE PT PT PT PT PT UK/H/0342/ /2012/02 BRITANNIA EMA/578674/2016 Page 10/21

11 National Number UK/H/0342/ /2012/09 BRITANNIA UK/H/0342/ /2012/07 BRITANNIA UK/H/0342/ /2012/08 BRITANNIA UK/H/0342/ /2012/05 BRITANNIA UK/H/0342/ /2012/12 BRITANNIA UK/H/0342/ /2012/11 BRITANNIA UK/H/0342/ /2012/06 BRITANNIA UK/H/0342/ /2012/04 BRITANNIA UK/H/0342/ /2012/10 BRITANNIA EMA/578674/2016 Page 11/21

12 APO-go Ampullen 10 mg/ml oplossing voor injectie of infusie APO-go, 10mg/ml süstevõi infusioonilahus National Number UK/H/0342/002 RVG BRITANNIA UK/H/0342/ BRITANNIA NL EE APO-go 10 mg/ml Solución Inyectable o para Perfusión en Ampollas APO-go AMPOULES 10 mg/ml Solution for Injection or Infusion Apomorphin Archimedes 10 mg/ml Injektionslösung/Infusion slösung Apomorphinhydrochlorid 10 mg/ml Injektionslösung/Infusion slösung Apomorfina Archimedes 10 mg/ml solución inyectable/para perfusión Apomorphine hydrochloride 10mg/ml solution for injection/infusion UK/H/0342/ BRITANNIA UK/H/0342/002 PL 04483/0072 BRITANNIA UK/H/3238/001 ZUL NR ARCHIMEDES PHARMA UK LIMITED UK/H/3238/ ARCHIMEDES PHARMA UK LIMITED UK/H/3238/ ARCHIMEDES PHARMA UK LIMITED UK/H/3238/001 PL12406/0024 ARCHIMEDES PHARMA UK LIMITED ES UK AT DE ES UK EMA/578674/2016 Page 12/21

13 Apomorphin hameln rds 10 mg/ml Injektions- /Infusionslösung APO-go Pumpfill 5 mg/ml infusionsvätska, lösning i förfylld spruta APO-go PFS, 5 mg/ml, roztwór do infuzji National Number AT/H/0365/001/DC HAMELN RDS GMBH AT UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA SE PL Britaject 5 mg/ml oldatos infúzió előretöltött fecskendőben Britaject 5 mg/ml infusjonsvæske, oppløsning i ferdigfylt sprøyte Apo-go 5mg/ml Solução para perfusão em seringa pré-cheia APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe APO-go Pumpfill 5mg/ml innrennslislyf, lausn í áfylltri sprautu UK/H/0342/003 OGYI-T-22069/04 BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/003 PL 04483/0074 BRITANNIA UK/H/0342/003 PA0356/10/3 BRITANNIA UK/H/0342/003 IS/1/11/073/01 BRITANNIA HU NO PT UK IE IS EMA/578674/2016 Page 13/21

14 APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe APO-go 5 mg/ml infúzny roztok naplnený v injekčnej striekačke APO-go 5 mg/ml Infusionslösung in einer Fertigspritze APO-go 5 mg/ml Infusionslösung in einer Fertigspritze APO-go 5 mg/ml oplossing voor infusie in een voorgevulde spuit APO-go PFS 5 mg/ml Solución para Perfusión en Jeringa Precargada Apomorfine hydrochloride PharmSwed 5 mg/ml, oplossing voor infusie Apomorfin PharmSwed 5 mg/ml infusjonsvæske, oppløsning Apomorfin PharmSwed 5 mg/ml innrennslislyf, lausn National Number UK/H/0342/003 MA 957/00101 BRITANNIA UK/H/0342/003 27/0463/11-S BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA UK/H/0342/003 RVG BRITANNIA UK/H/0342/ BRITANNIA SE/H/1272/001 RVG PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/ PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/001 IS71/12/122/01 PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB MT SK AT DE NL ES NL NO IS EMA/578674/2016 Page 14/21

15 Apomorfin PharmSwed, infusionsvæske, opløsning Apomorphine hydrochloride 5mg/ml solution for infusion Apomorphine hydrochloride 5 mg/ml, solution for infusion Apomorphinhydrochlorid PharmSwed 5 mg/ml Infusionslösung Apomorfin PharmSwed 5 mg/ml, infusionsvätska, lösning APO-go PEN oplossing voor injectie 10 mg/ml National Number SE/H/1272/ PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/001 PA1807/001/001 PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/001 PL 41183/0001 PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/ PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB SE/H/1272/ PharmSwed PHARMACEUTICALS SALES & DEVELOPMENT SWEDEN AB UK/H/0342/001 RVG BRITANNIA DK IE UK DE SE NL APO go PEN, 10 mg/ml, roztwór do wstrzykiwan UK/H/0342/ BRITANNIA PL APO-GO-PEN 10 mg/ml oplossing voor injectie UK/H/0342/001 BE BRITANNIA BE Britaject PEN 10 mg/ml oldatos injekció UK/H/0342/001 OGYI-T-22069/01 BRITANNIA HU EMA/578674/2016 Page 15/21

16 Britaject 10 mg/ml injeksjonsvæske, oppløsning i ferdigfylt penn. solução injetável National Number UK/H/0342/ BRITANNIA UK/H/0342/ BRITANNIA NO PT APO-go 10 mg/ml raztopina za injiciranje v peresniku Solution for Injection UK/H/0342/ I-671/12 BRITANNIA UK/H/0342/001 PL 04483/0073 BRITANNIA SI UK Solution for Injection UK/H/0342/ PA0356/10/1 BRITANNIA IE Britaject PEN 10mg/ml injekcinis tirpalas UK/H/0342/001 LT/1/12/2917/007 BRITANNIA LT solução injetável UK/H/0342/ BRITANNIA PT solução injetável UK/H/0342/ BRITANNIA PT Solution for Injection UK/H/0342/001 MA 957/00102 BRITANNIA MT EMA/578674/2016 Page 16/21

17 Apogo PEN 10 mg/ml injektioneste, liuos National Number UK/H/0342/ BRITANNIA FI APO-go Pen, injektionsvæske, opløsning АПО-го ПИСАЛКА 10 mg/ml инжекционен разтвор APO-go 10 mg/ml injekčný roztok naplnený v pere solución inyectable UK/H/0342/ BRITANNIA UK/H/0342/001 R-8828 BRITANNIA UK/H/0342/001 27/0462/11-S BRITANNIA UK/H/0342/ BRITANNIA DK BG SK ES Injektionslösung UK/H/0342/ BRITANNIA DE stungulyf, lausn UK/H/0342/001 IS/1/11/072/01 BRITANNIA IS šķīdums injekcijām UK/H/0342/ BRITANNIA LV Britaject PEN 10 mg/ml injekční roztok UK/H/0342/001 27/787/11-C BRITANNIA CZ EMA/578674/2016 Page 17/21

18 APO-go PEN 10 mg/ml Injektionslösung National Number UK/H/0342/ BRITANNIA AT injektionsvätska, lösning UK/H/0342/ BRITANNIA SE Apomorphine hameln rds AT/H/0365/001/DC n/a HAMELN RDS GMBH FR 10mg/ml, solution jejectable/pour perfusion APO-go Ampoules UK/H/0342/ R-8971/ BRITANNIA BG Britaject UK/H/0342/ LT/1/12/2917/ BRITANNIA LT APO-GO-AMP UK/H/0342/ BRITANNIA LU APO-go 10 mg/ml raztopina za injiciranje ali infundiranje v ampuli UK/H/0342/ I-672/12 BRITANNIA APO-go PEN UK/H/0342/ ML BRITANNIA SI CY APO-go UK/H/0342/ /01/3989 BRITANNIA EE EMA/578674/2016 Page 18/21

19 National Number APO-go PEN UK/H/0342/ / BRITANNIA GR APO-go PEN UK/H/0342/ BRITANNIA LU Apo-go PEN UK/H/0342/ /2012/10-12 BRITANNIA Apo-go PFS UK/H/0342/ R-8829/ BRITANNIA BG APO-go PFS UK/H/0342/ ML BRITANNIA CY APO-go PFS UK/H/0342/ BRITANNIA GR APO-go PFS UK/H/0342/ BRITANNIA LU APO-go UK/H/0342/ /2012/01-12 BRITANNIA Dopaceptin AT/H/0364/001/DC EVER NEU PHARMA GMBH GR EMA/578674/2016 Page 19/21

20 National Number Dopaceptin AT/H/0364/002/DC 49653/ EVER NEU PHARMA GMBH GR Dacepton AT/H/0364/002/ DC EVER NEU PHARMA GMBH PL APOFIN 50 mg/5 ml soluzione iniettabile per infusione sottocutanea not available CHIESI FARMACEUTICI S.P.A. APOFIN STYLO not available CHIESI FARMACEUTICI S.P.A. IT IT APOFIN STYLO not available CHIESI FARMACEUTICI S.P.A. IT BRITAJECT 10 mg/ml oldatos injekció vagy infúzió Apokinon 10 mg/ml, solution injecatble (SC) UK/H/0342/002 OGYI-T-22069/02-03 BRITANNIA HU NL Laboratoire AGUETTANT FR Apokinon 30 mg/3 ml, solution injecatble en stylo pré-rempli Apokinon 5 mg/ml, solution injecatble NL Laboratoire AGUETTANT FR NL Laboratoire AGUETTANT FR EMA/578674/2016 Page 20/21

21 National Number Apomorphin Teclapharm GmbH DE EMA/578674/2016 Page 21/21

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 September 2017 EMA/604559/2017 Human Medicines Evaluation Division Active substance: iron / parenteral preparations Procedure no.: PSUSA/00010236/201701 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/227889/2018 Human Medicines Evaluation Division Active substance(s): typhoid polysaccharide vaccine Procedure No.: PSUSA/00003065/201708 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/795271/2017 Human Medicines Evaluation Division Active substance: vinorelbine Procedure no.: PSUSA/00003124/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 09 June 2017 EMA/36849/2017 Human Medicines Evaluation Division Active substance(s): brimonidine / timolol Procedure No.: PSUSA/00000431/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/690754/2017 Human Medicines Evaluation Division Active substance: fish oil / olive oil / soybean oil / triglycerides mediumchain Procedure no.: PSUSA/00010223/201702 30 Churchill Place

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 14 April 2016 EMA/284169/2016 Procedure Management and Committees Support Active substance: influenza vaccine (split virion, inactivated) (non centrally products) Procedure no.: PSUSA/00010298/201508 30

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride

PACKAGE LEAFLET: INFORMATION FOR THE USER. NALOXONE 400 microgram/ml solution for injection or infusion. naloxone hydrochloride PACKAGE LEAFLET 1 PACKAGE LEAFLET: INFORMATION FOR THE USER NALOXONE 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/658449/2017 Human Medicines Evaluation Division Active substance: olodaterol Procedure no.: PSUSA/00010245/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults

APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults APO-go PFS 5mg/ml Solution for Infusion in Pre-filled Syringe apomorphine hydrochloride 50mg/10ml For use in adults Package Leaflet: Information for the User Read all of this leaflet carefully before you

More information

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride

Package leaflet: Information for the user. Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Package leaflet: Information for the user Naloxone 400 microgram/ml solution for injection or infusion naloxone hydrochloride Read all of this leaflet carefully before you start using this medicine because

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/677092/2015 Procedure Management and Committees Support Active substance: glatiramer Procedure no.: PSUSA/00001529/201411 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/223740/2018 Human Medicines Evaluation Division Active substance: fludarabine Procedure no.: PSUSA/00001406/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/615391/2018 Human Medicines Evaluation Division Active substance: tobramycin (nebuliser solution) (apart from centrally authorised product) Procedure no.: PSUSA/00009316/201712 30

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 September 2017 EMA/580096/2017 Human Medicines Evaluation Division Active substance: terbutaline Procedure no.: PSUSA/00002897/201612 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817337/2017 Human Medicines Evaluation Division Active substance: Itraconazole Procedure no.: PSUSA/00001798/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/497430/2018 Human Medicines Evaluation Division Active substance: tafluprost / timolol Procedure no.: PSUSA/00010324/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/691535/2017 Human Medicines Evaluation Division Active substance: Haemophilus type b conjugate vaccines Procedure no.: PSUSA/00001584/201702 30 Churchill Place Canary Wharf London E14

More information

PACKAGE LEAFLET: Information for the User

PACKAGE LEAFLET: Information for the User PACKAGE LEAFLET: Information for the User APO-go PEN 10mg/ml Solution for Injection * Apomorphine hydrochloride * Abbreviated to APO-go Pen in the text Read all of this leaflet carefully before you start

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 1 December 2016 EMA/750653/2016 Human Medicines Evaluation Division Active substance: valganciclovir Procedure no.: PSUSA/00003089/201603 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 May 2017 EMA/288255/2017 Human Medicines Evaluation Division Active substance: pilocarpine (ophthalmic formulation) Procedure no.: PSUSA/00002410/201608 30 Churchill Place Canary Wharf London E14 5EU

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 13 September 2017 EMA/706786/2017 Human Medicines Evaluation Division Active substance: Octenidine dihydrochloride / phenoxyethanol Procedure no.: PSUSA/00002199/201701 30 Churchill Place Canary Wharf

More information

PATIENT INFORMATION LEAFLET. Midazolam 5 mg/ml Solution for Injection or Infusion midazolam

PATIENT INFORMATION LEAFLET. Midazolam 5 mg/ml Solution for Injection or Infusion midazolam PATIENT INFORMATION LEAFLET Midazolam 1 mg/ml Solution for Injection or Infusion Midazolam 5 mg/ml Solution for Injection or Infusion midazolam Read all of this leaflet carefully before you start taking

More information

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin

Package leaflet: Information for the user. Rhesonativ 625 IU/ml, solution for injection Human anti-d immunoglobulin Package leaflet: Information for the user Human anti-d immunoglobulin Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/622830/2015 Procedure Management and Committees Support Active substance: azelastine Procedure no.: PSUSA/00000277/201412 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 10 September 2015 EMA/612853/2015 Procedure Management and Committees Support Active substance: tobramycin (nebuliser solution) Procedure no.: PSUSA/00009316/201412 30 Churchill Place Canary Wharf London

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 January 2017 EMA/36356/2017 Human Medicines Evaluation Division Active substance: hydroxyzine chloride / hydroxyzine pamoate and all fixed combination, hydroxyzine Procedure no.: PSUSA/00001696/201605

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 28 September 2017 EMA/639167/2017 Human Medicines Evaluation Division Active substance: zanamivir Procedure no.: PSUSA/00003141/201701 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 17 May 2018 EMA/303456/2018 Human Medicines Evaluation Division Active substance: bromazepam Procedure no.: PSUSA/00000435/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 October 2017 EMA/784453/2017 Human Medicines Evaluation Division List of nationally authorised medicinal products Active substance(s): ipratropium / salbutamol Procedure No.: PSUSA/00001781/201701 30

More information

V007 B. PACKAGE LEAFLET

V007 B. PACKAGE LEAFLET B. PACKAGE LEAFLET Package leaflet: Information for the user Fyremadel 0.25 mg/0.5 ml solution for injection in pre-filled syringe ganirelix Read all of this leaflet carefully before you start using this

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant

PACKAGE LEAFLET: INFORMATION FOR THE USER. FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant PACKAGE LEAFLET: INFORMATION FOR THE USER FULVESTRANT TEVA 250 mg SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE Fulvestrant Read all of this leaflet carefully before you start using this medicine because

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 November 2018 EMA/880324/2018 Human Medicines Evaluation Division Active substance: enalapril Procedure no.: PSUSA/00001211/201803 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user

Package leaflet: Information for the user Package leaflet: Information for the user Lidocaine Accord 10 mg/ml solution for injection Lidocaine Accord 20 mg/ml solution for injection Lidocaine hydrochloride Read all of this leaflet carefully before

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 21 June 2017 EMA/610895/2017 Human Medicines Evaluation Division Active substance: felbamate Procedure no.: PSUSA/00010155/201609 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/812360/2017 Human Medicines Evaluation Division Active substance(s): mupirocin Procedure No.: PSUSA/00002096/201703 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182668/2018 Human Medicines Evaluation Division Active substance(s): triamcinolone (topical and nasal formulations) Procedure No.: PSUSA/00003017/201707 30 Churchill Place Canary Wharf

More information

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride

PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER. Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride Page 1 PACKAGE LEAFLET PACKAGE LEAFLET: INFORMATION FOR THE USER Prilotekal 20 mg/ml solution for injection prilocaine hydrochloride Read all of this leaflet carefully before you are given this medicine

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/608492/2018 Human Medicines Evaluation Division Active substance: betahistine Procedure no.: PSUSA/00000389/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/612350/2018 Human Medicines Evaluation Division Active substance: azelastine Procedure no.: PSUSA/00000277/201712 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 01 December 2016 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00002591/201604 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile

More information

Module Page 1 of 1

Module Page 1 of 1 Bupivacaine solution for Injection 2.5 mg / ml and 5 mg / ml 1.3 Product information 1.3.1 SPC, labelling and package leaflet 1.3.1.1 Package leaflet Enclosed in subsequent pages, Module 1.3.1 Page 1 of

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 06 July 2017 EMA/436040/2017 Human Medicines Evaluation Division Active substance: Procedure no.: PSUSA/00001815/201610 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Naloxone 400 micrograms/ml solution for injection/infusion. naloxone hydrochoride

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT. Naloxone 400 micrograms/ml solution for injection/infusion. naloxone hydrochoride PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Naloxone 400 micrograms/ml solution for injection/infusion naloxone hydrochoride Read all of this leaflet carefully before this medicine is administered to

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 08 March 2018 EMA/170163/2018 Human Medicines Evaluation Division Active substance: enalapril / hydrochlorothiazide Procedure no.: PSUSA/00001212/201707 30 Churchill Place Canary Wharf London E14 5EU United

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/231137/2018 Human Medicines Evaluation Division Active substance: fluvoxamine Procedure no.: PSUSA/00001458/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 January 2018 EMA/24585/2018 Human Medicines Evaluation Division Active substance: esomeprazole / naproxen Procedure no.: PSUSA/00001270/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 29 September 2017 EMA/658556/2017 Procedure Management and Committees Support Active substance: loratadine Procedure no.: PSU/00001907/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 5 November 2015 EMA/230130/2016 Procedure Management and Committees Support Active substance: cabergoline Procedure no.: PSUSA/00000477/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/817351/2017 Human Medicines Evaluation Division Active substance: Lidocaine / prilocaine (not centrally authorised product) Procedure no.: PSUSA/00001867/201703 30 Churchill Place

More information

Package leaflet: Information for the patient. Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid

Package leaflet: Information for the patient. Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid Package leaflet: Information for the patient Leucovorine Sandoz 10 mg/ml, oplossing voor injectie folinic acid Read all of this leaflet carefully before you start using this medicine because it contains

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 30 November 2017 EMA/806830/2017 Human Medicines Evaluation Division Active substance: piroxicam Procedure no.: PSUSA/00002438/201704 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 July 2018 EMA/462856/2018 Human Medicines Evaluation Division Active substance: econazole, econazole nitrate / triamcinolone acetonide, econazole nitrate / zinc oxide Procedure no.: PSUSA/00001195/201711

More information

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you. Due to regulatory changes, the content of the following Patient Information Leaflet may vary from the one found in your medicine pack. Please compare the 'Leaflet prepared/revised date' towards the end

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion

PACKAGE LEAFLET: INFORMATION FOR THE USER. ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion PACKAGE LEAFLET: INFORMATION FOR THE USER ESMOCARD LYO 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using this medicine.

More information

Package leaflet: Information for the patient. Ropivacaine 2 mg/ml solution for infusion in administration system. Ropivacaine hydrochloride

Package leaflet: Information for the patient. Ropivacaine 2 mg/ml solution for infusion in administration system. Ropivacaine hydrochloride Package leaflet: Information for the patient Ropivacaine 2 mg/ml solution for infusion in administration system Ropivacaine hydrochloride Read all of this leaflet carefully before this medicine is given

More information

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES

ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTES OF ADMINISTRATION, APPLICANTS IN THE MEMBER STATES 1 Member State EU/EEA Marketing Authorisation Holder Austria

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 27 October 2016 EMA/719205/2016 Human Medicines Evaluation Division Active substance: ethinylestradiol / gestodene (except for transdermal application) Procedure no.: PSUSA/00001308/201603 30 Churchill

More information

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO

Implementation Report on the patient safety Recommendation 2009/C 151/01. Healthcare Systems Unit DG SANCO Implementation Report on the patient safety Recommendation 2009/C 151/01 Healthcare Systems Unit DG SANCO Published 15 November 2012 REPORT FROM THE COMMISSION TO THE COUNCIL on the basis of Member States'

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/382206/2018 Human Medicines Evaluation Division Active substance(s): naproxen Procedure No.: PSUSA/00002125/201708 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

Package leaflet: Information for the user. Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin

Package leaflet: Information for the user. Gammanorm, 165 mg/ml, solution for injection Human normal immunoglobulin Package leaflet: Information for the user, 165 mg/ml, solution for injection Human normal immunoglobulin Read all of this leaflet carefully before you start using this medicine because it contains important

More information

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion

Package leaflet: Information for the user. ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Package leaflet: Information for the user ESMOLOL HYDROCHLORIDE 2500 mg powder for concentrate for solution for infusion Esmolol hydrochloride Read all of this leaflet carefully before you start using

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 26 October 2017 EMA/663700/2017 Human Medicines Evaluation Division Active substance: cromoglicic acid Procedure no.: PSUSA/00000883/201702 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine

Package leaflet: Information for the user. Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Package leaflet: Information for the user Gemcitabine Fresenius Kabi 40 mg/ml, concentraat voor oplossing voor infusie Gemcitabine Read all of this leaflet carefully before you start using this medicine

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate

PACKAGE LEAFLET: INFORMATION FOR THE USER. Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate PACKAGE LEAFLET: INFORMATION FOR THE USER Methofill 50 mg/ml solution for injection in pre-filled syringe methotrexate Read all of this leaflet carefully before you start using this medicine because it

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 3 December 2015 EMA/98477/2016 Procedure Management and Committees Support Active substance: acarbose Procedure no.: PSUSA/00000017/201503 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 8 March 2018 EMA/182904/2018 Human Medicines Evaluation Division Active substance(s): fluticasone propionate / formoterol fumarate dihydrate Procedure No.: PSUSA/00010339/201707 30 Churchill Place Canary

More information

Package leaflet: Information for the user. Sterofundin ISO solution for infusion

Package leaflet: Information for the user. Sterofundin ISO solution for infusion Package leaflet: Information for the user solution for infusion Read all of this leaflet carefully before you start using this medicine because it contains important information for you. - Keep this leaflet.

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 6 September 2018 EMA/619619/2018 Human Medicines Evaluation Division Active substance: haemophilus influenzae / klebsiella ozaenae / klebsiella pneumoniae / moraxella catarrhalis / staphylococcus aureus

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER biosyn Arzneimittel GmbH Schorndorfer Strasse 32, 70734 Fellbach, Germany PACKAGE LEAFLET: INFORMATION FOR THE USER Selenase 100 micrograms, solution for injection (50 micrograms/ml) 100 microgram selenium

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 7 July 2016 EMA/437334/2016 Procedure Management and Committees Support Division Active substance: Terazosin Procedure no.: PSUSA/00002895/201511 30 Churchill Place Canary Wharf London E14 5EU United Kingdom

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN)

PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) PACKAGE LEAFLET: INFORMATION FOR THE USER OXALIPLATIN 5 MG/ML POWDER FOR SOLUTION FOR INFUSION (OXALIPLATIN) Read all of this leaflet carefully before you are given Oxaliplatin. - Keep this leaflet. You

More information

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008

EUROPEAN MEDICINES AGENCY DECISION. of 20 July 2008 European Medicines Agency Doc. Ref. EMEA/357907/2008 P/53/2008 EUROPEAN MEDICINES AGENCY DECISION of 20 July 2008 on the application for agreement of a Paediatric Investigation Plan for Atorvastatin calcium

More information

Voluven 10 % solution for infusion Hydroxyethyl starch (HES 130/0.4) in isotonic sodium chloride solution

Voluven 10 % solution for infusion Hydroxyethyl starch (HES 130/0.4) in isotonic sodium chloride solution 0xxxxx1_00_UK_Voluven_10%_V003:0xxxxx1_00_UK_Voluven_10%_V003 10.02.2016 10:36 Uhr Seite 1 5 6 1 Electrolytes: Na + 154 mmol/l Cl 154 mmol/l Theoretical osmolarity: 308 mosm/l Titrable acidity: 1.0 mmol

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 12 April 2018 EMA/243033/2018 Human Medicines Evaluation Division Active substance: fenofibrate Procedure no.: PSUSA/00001362/201707 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone

More information

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use

(Invented) Name Strength Pharmaceutical Form. 3 mg/3 ml Solution for injection. Kytril 2 mg - Filmtabletten 2 mg Film-coated tablet Oral use ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORMS, STRENGTHS OF THE MEDICINAL PRODUCTS, ROUTES OF ADMINISTRATION, MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES 1 Austria Austria Bulgaria Bulgaria

More information

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol

Package leaflet: Information for the patient. Paracetamol 10 mg/ml solution for infusion. Paracetamol Package leaflet: Information for the patient Paracetamol Read all of this leaflet carefully before you are given this medicine because it contains important information for you. - Keep this leaflet. You

More information

Trends in injecting drug use in Europe

Trends in injecting drug use in Europe Trends in injecting drug use in Europe Linda Montanari, Bruno Guarita and Danica Thanki Annual Expert Meeting on Drug-Related Infectious Diseases Lisbon, 15-17 October Overview of the presentation 1) Information

More information

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective

Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Public administration reforms and public sector performance in Central and Eastern Europe EU member states: in EU perspective Prof. Ing. Juraj Nemec, CSc. Masaryk University, Czech Republic, Size of government

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER

PACKAGE LEAFLET: INFORMATION FOR THE USER PACKAGE LEAFLET: INFORMATION FOR THE USER OCTAGAM 10%, solution for infusion Human Normal Immunoglobulin (IVIg) Read all of this leaflet carefully before you start using this medicine because it contains

More information

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH

Pharmaceutical Pricing & Reimbursement Information. PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI - Comparative Analysis PPRI Project Co-ordination Sabine Vogler, Gesundheit Österreich GmbH PPRI Conference Vienna, 29 June 2007 PPRI Conference, Vienna, 29 June 2007 1 Comparative Analysis - Outline

More information

European Union herbal monograph on Pistacia lentiscus L., resin (mastix)

European Union herbal monograph on Pistacia lentiscus L., resin (mastix) 7 July 2015 EMA/HMPC/46758/2015 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Pistacia lentiscus L., resin (mastix) Draft Discussion in Working Party on European Union

More information

PART I.B. Laboratoire TVM DIAZEPAM TVM / ZIAPAM, 5 MG/ML, SOLUTION FOR INJECTION FOR

PART I.B. Laboratoire TVM DIAZEPAM TVM / ZIAPAM, 5 MG/ML, SOLUTION FOR INJECTION FOR PART I.B 1 TABLE OF CONTENT PART I.B: SPC, LABELLING AND PACKAGE INSERT Pages 1.b.1 Summary of product characteristics (SPC)... 3 1.b.2 Labelling and Package... 8 1.b.2.a Labelling... Unchanged 1.b.2.b

More information

Package leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie

Package leaflet: Information for the patient. Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Package leaflet: Information for the patient Rapibloc 300 mg poeder voor oplossing voor infusie Rapibloc 600 mg poeder voor oplossing voor infusie Landiolol hydrochloride This medicine is subject to additional

More information

European Union herbal monograph on Eschscholzia californica Cham., herba

European Union herbal monograph on Eschscholzia californica Cham., herba 28 January 2015 EMA/HMPC/680372/2013 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Eschscholzia californica Cham., herba Final Discussion in Working Party on European

More information

List of nationally authorised medicinal products

List of nationally authorised medicinal products 11 February 2016 EMA/255959/2016 Procedure Management and Committees Support Active substance: calcitonin salmon, synthetic analogue of eel calcitonin Procedure No.: PSUSA/00000494/201506 30 Churchill

More information

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014

VARIATIONS : IMPACT ON ADMINISTRATIVE BURDEN AND FEES. Rose-Marie Molina EMA Infoday London, 14th March 2014 Rose-Marie Molina EMA Infoday London, 14th March 2014 Before 1234/2008 Regulation, variation procedures in the European Union for industry was synonymous of: - Lack of visibility about timelines - Lack

More information

European Union herbal monograph on Peumus boldus Molina, folium

European Union herbal monograph on Peumus boldus Molina, folium 22 November 2016 EMA/HMPC/453725/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Peumus boldus Molina, folium Final Initial assessment Discussion in Working Party

More information

B. PACKAGE LEAFLET R001 1

B. PACKAGE LEAFLET R001 1 B. PACKAGE LEAFLET R001 1 Package leaflet: Information for the user Terlipressin acetate 0.12 mg/ml solution for injection terlipressin (as acetate) Read all of this leaflet carefully before you are given

More information

Package leaflet: Information for the user. {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection

Package leaflet: Information for the user. {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection Package leaflet: Information for the user {Product name} 100 mg/100 mg/1 mg/20 mg/2 ml solution for injection Pyridoxini hydrochloridum, Thiamini hydrochloridum, Cyanocobalaminum, Lidocaini hydrochloridum

More information

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities

Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Ensuring protection of public health and patients in member states: priorities, constraints, opportunities Dr. Christa Wirthumer-Hoche AGES Austrian Medicines and Medical Devices Agency Vienna, Austria

More information

PACKAGE LEAFLET: INFORMATION FOR THE USER. Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie

PACKAGE LEAFLET: INFORMATION FOR THE USER. Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie PACKAGE LEAFLET: INFORMATION FOR THE USER Secretine Iberoinvesa Pharma S.L. 100 E, poeder en oplosmiddel voor oplossing voor injectie/infusie Secretin pentahydrochloride Read all of this leaflet carefully

More information

Initial (Full) Marketing Authorisation application accelerated assessment timetables

Initial (Full) Marketing Authorisation application accelerated assessment timetables 30 Churchill Place Canary Wharf London E14 5EU United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact An agency of the European

More information

European Medicines Agency decision

European Medicines Agency decision EMA/501681/2016 European Medicines Agency decision P/0213/2016 of 12 August 2016 on the acceptance of a modification of an agreed paediatric investigation plan for benralizumab (EMEA- 001214-PIP01-11-M05)

More information

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba

European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba 24 November 2015 EMA/HMPC/712511/2014 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Epilobium angustifolium L. and/or Epilobium parviflorum Schreb., herba Final Discussion

More information

European Union herbal monograph on Glycine max (L.) Merr., lecithinum

European Union herbal monograph on Glycine max (L.) Merr., lecithinum 31 January 2017 EMA/HMPC/220599/2016 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Glycine max (L.) Merr., lecithinum Final Discussion in Working Party on European Union

More information

European Union herbal monograph on Ruscus aculeatus L. rhizoma

European Union herbal monograph on Ruscus aculeatus L. rhizoma 30 January 2018 EMA/188804/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Ruscus aculeatus L. rhizoma Draft Initial assessment Discussion in Working Party on European

More information

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma

European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), rhizoma 21 November 2017 EMA/HMPC/329755/2017 Committee on Herbal Medicinal Products (HMPC) European Union herbal monograph on Curcuma longa L. (C. domestica Valeton), Draft Initial assessment Discussion in Working

More information

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81

LIMITE EN COUNCIL OF THE EUROPEAN UNION. Brussels, 7 July /11 LIMITE ENFOPOL 228 DAPIX 81 COUNCIL OF THE EUROPEAN UNION Brussels, 7 July 2011 12390/11 LIMITE ENFOPOL 228 DAPIX 81 NOTE From: Presidency To: Law Enforcement Working Party No. prev. doc.: CM 1508/11 Subject: Results of the questionnaire

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics

Finnish international trade 2017 Figures and diagrams. Finnish Customs Statistics Finnish international trade 217 Figures and diagrams Finnish Customs Statistics IMPORTS, EXPORTS AND TRADE BALANCE 199-217 Billion e 7 6 5 4 3 2 1-1 9 91 92 93 94 95 96 97 98 99 1 2 3 4 5 6 7 8 9 1 11

More information